KGKasper Smidt Gasbjerg

Kasper Smidt Gasbjerg

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kasper Smidt Gasbjerg has a total of 70 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Whole Blood Transcriptomic Response to Perioperative Dexamethasone in Total Knee Arthroplasty: A Targeted Panel Analysis

    by Asger Krog Mølgaard, Kasper Smidt Gasbjerg, Lukas Balsevicius, Britt Cappelen, Adile Orhan, Helin Yikilmaz Pardes, Ole Mathiesen, Thomas Litman, Daniel Hägi‐Pedersen, Ismail Gögenur

    Background: Changes in the transcriptome of immune cells are predictive of clinical outcomes. These effects may be surgery‐specific and possibly modulated by glucocorticoids. We investigated the immune response and the impact of dexamethasone on the response in patients undergoing total knee arthroplasty (TKA). Methods: The transcript levels ( n = 579) in whole blood of 63 patients undergoing TKA and receiving either dexamethasone (DXM, n = 46) or placebo ( n = 17) perioperatively were characterised by the Nanostring nCounter platform and the Immunology V2 panel. Samples were collected before surgery and on the first postoperative day (POD1). Results: Dexamethasone induced differential expression of 113 genes (|log2 fold change| > 0.5, adjusted p ‐value [ p ‐adj] < 0.05). Pathway enrichment analysis using an Over‐Representation Analysis (ORA) indicated an up‐regulation of IL6/JAK‐STAT3‐signalling ( p ‐adj 0.016) and down‐regulation of a pathway related to allograft‐rejection ( p ‐adj 0.032). The immune response itself induced differential expression of 169 genes and ORA only found an allograft rejection pathway significant ( p ‐adj 0.016). Cell type deconvolution indicated that dexamethasone increased the granulocyte fraction (69.6% vs. 73.6%, p ‐adj = 0.005) and reduced B‐ and Plasma‐cell fraction (10.1% vs. 8.4%, p ‐adj = 0.016). The granulocyte fraction on POD1 was significantly different between dexamethasone and placebo‐treated patients (73.6% vs. 70.1%, p ‐adj = 0.048). Conclusions: Perioperative dexamethasone in TKA induced differential expression of genes related to IL6‐JAK/STAT3‐signalling as estimated by the Immunology V2 panel. This, however, is not supported by the literature or a rank‐based interpretation of the most differentially expressed genes and was most likely due to technical reasons. Future studies should focus on broader panels, different techniques or measures leading to fewer exclusions of genes during quality control when seeking to characterise the immune response to TKA and dexamethasone. Editorial Comment: This transcriptomic sub‑study shows that perioperative dexamethasone does not simply suppress, but distinctly reshapes, the early whole‑blood immune response to total knee arthroplasty. However, the study investigated an early postoperative snapshot after a single perioperative dose only. Thus, longitudinal linkage to circulating biomarkers of inflammation and injury as well as clinical outcomes could not be assessed. This study therefore should be regarded as hypothesis‑generating, urging for extended, multi‑modal and outcome‑oriented studies before concluding on the broader clinical effects of perioperative dexamethasone.

  • Open Access

    The Adverse Effects Associated With Ibuprofen Use After Major Orthopaedic Surgeries—A Detailed Statistical Analysis Plan for the PERISAFE Randomized Clinical Trial

    by Christina C. W. Laursen, Troels H. Lunn, Daniel Hägi‐Pedersen, Markus Harboe Olsen, Andreas Kappel, Thomas Jakobsen, Niels A. Pedersen, Thomas Thougaard, Ben K. Graungaard, Thomas Bjerno, et al.

    The PERISAFE trial aims to assess the adverse effects associated with an 8‐day postoperative treatment with ibuprofen after hip and knee arthroplasties. This paper outlines the detailed statistical analysis plan for the primary data. The PERISAFE trial is a randomized, placebo‐controlled, blinded multicentre trial allocating 2904 hip‐ or knee‐arthroplasty patients 1:1 to ibuprofen 400 mg ×3/day or identical placebo ×3/day for 8 days postoperatively. The primary outcome is a composite of death, acute myocardial infarction, stroke, pulmonary embolism, deep venous thrombosis, renal failure, major bleeding, re‐operation, gastrointestinal ulcer, or readmission within 90 days postoperatively. Secondary outcomes are hospital‐free days within 90 days postoperatively, a composite of ibuprofen and opioid‐related adverse reactions based on an 8‐day postoperative diary, and health‐related quality of life after 90 days postoperatively. All randomized patients who undergo surgery will be included in all analyzes. Binary data will be analyzed using a mixed‐effects generalized linear model, count data will be analyzed using the van Elteren test, and continuous data will be analyzed using a mixed‐effects linear regression. Additionally, the win ratio will be calculated for the primary outcome. The statistical analyzes will be conducted in accordance with this pre‐planned statistical analysis plan with one interim analysis after the inclusion of 1400 patients. All analyzes will be adjusted for site. We expect that the PERISAFE trial will provide high‐quality data based on predefined detailed methodology regarding the safety of postoperative treatment with ibuprofen after elective hip and knee arthroplasties.


  • The adverse effects with ibuprofen after major orthopedic surgeries: A protocol for the PERISAFE randomized clinical trial

    by Christina Cleveland Westerdahl Laursen, Troels Haxholdt Lunn, Daniel Hägi‐Pedersen, Anne Sofie Nautrup Therkelsen, Claus Varnum, Kai Henrik Wiborg Lange, Müjgan Yilmaz, Niels Anker Pedersen, Andreas Kappel, Thomas Jakobsen, et al.

    Introduction: Non‐steroidal anti‐inflammatory drugs (NSAIDs) are recommended for pain treatment after elective hip and knee arthroplasties. However, evidence regarding the incidence of adverse effects with short‐term NSAID treatment following surgery is limited. We, therefore, aim to assess the adverse effects with an eight‐day postoperative treatment with ibuprofen after elective hip and knee arthroplasties.Methods and Analysis: PERISAFE is a randomized, placebo‐controlled, blinded multicenter trial with 90‐day and one‐year follow‐up. Eligible patients undergoing elective hip or knee arthroplasty are allocated 1:1 to either ibuprofen 400 mg ×3/day or identical placebo ×3/day for eight days after surgery. The primary outcome is a composite of either death, acute myocardial infarction, stroke, pulmonary embolism, deep venous thrombosis, renal failure, major bleeding, re‐operation, gastrointestinal ulcer, or readmission within 90 days postoperatively. Secondary outcomes are hospital‐free days within 90 days postoperatively, a composite of ibuprofen and opioid‐related adverse reactions based on eight‐day postoperative diary, and health related quality of life after 90 days postoperatively.A total of 2904 patients are needed to demonstrate a relative risk reduction of 33% in the placebo group, accepting a risk of type I error of 5% and type II error of 20% and a proportion of serious adverse events in the ibuprofen group of 8%. The primary analysis will be in the modified intention‐to‐treat population.Ethics and Dissemination: The trial is approved by the Danish Medicine Agency and the Research Ethics Committee (EU CT no. 2022‐502, 502‐32‐00). We plan to submit for publication in a major international peer‐reviewed journal and present results at scientific meetings.


  • Open Access

    Minimal important difference in postoperative morphine consumption after hip and knee arthroplasty using nausea, vomiting, sedation and dizziness as anchors

    by Anders Peder Højer Karlsen, Jens Laigaard, Casper Pedersen, Kasper Højgaard Thybo, Kasper Smidt Gasbjerg, Anja Geisler, Troels Haxholdt Lunn, Daniel Hägi‐Pedersen, Janus Christian Jakobsen, Ole Mathiesen

    Background: Morphine‐sparing effects are often used to evaluate non‐opioid analgesic interventions. The exact effect that would warrant the implementation of these interventions in clinical practice (a minimally important difference) remains unclear. We aimed to determine this with anchor‐based methods.Methods: This was a post hoc analysis of three studies investigating pain management after hip or knee arthroplasty (PANSAID [NCT02571361], DEX‐2‐TKA [NCT03506789] and Pain Map [NCT02340052]). The overall population was median aged 70, median ASA 2, 54% female. We examined the correlation between 0 and 24 h postoperative iv morphine equivalent consumption and the severity of nausea, vomiting, sedation and dizziness. The anchor was different severity degrees of these opioid‐related adverse events. The primary outcome was the difference in morphine consumption between patients experiencing no versus only mild events. Secondary outcomes included the difference in morphine consumption between patients with mild versus moderate and moderate versus severe events. We used Hodges–Lehmann median differences, exact Wilcoxon–Mann–Whitney tests and quantile regression.Results: The difference in iv morphine consumption was 6 mg (95% confidence interval: 4–8) between patients with no versus only mild events, 5 mg (2–8) between patients with mild versus moderate events and 0 mg (−4 to 4) between patients with moderate versus severe events.Conclusions: In populations comparable to this post‐hoc analysis (orthopaedic surgery, median age 70 and ASA 2), we suggest a minimally important difference of 5 mg for 0–24 h postoperative iv morphine consumption.


  • Open Access

    Associations of dexamethasone's effect on morphine consumption after total knee arthroplasty—Subgroup analyses

    by Kasper S. Gasbjerg, Troels H. Lunn, Daniel Hägi‐Pedersen, Søren Overgaard, Niels A. Pedersen, Peter Lindholm, Martin Lindberg‐Larsen, Stig Brorson, Henrik M. Schrøder, Kasper H. Thybo, et al.

    The DEXamethasone twice for pain treatment after Total Knee Arthroplasty (DEX‐2‐TKA) trial showed that adding one and two doses of 24 mg intravenous dexamethasone to paracetamol, ibuprofen and local infiltration analgesia, reduced morphine consumption (primary outcome) within 48 h after TKA. We aimed to explore the differences in the effect of dexamethasone on morphine consumption in different subgroups. Quantile regression adjusted for site was used to test for significant interaction between the predefined dichotomised subgroups and treatment group. The subgroups were defined based on baseline data: sex (male/female), age (≤65 years/>65 years), American Society of Anaesthesiologists (ASA)‐score (ASA I + II/III), visual analogue score of preoperative pain at rest (≤30 mm/>30 mm), pain during mobilisation (≤30 mm/>30 mm), type of anaesthesia (spinal anaesthesia/general anaesthesia and spinal converted to general anaesthesia), and prior daily use of analgesics (either paracetamol and/or NSAID/neither). These analyses were supplemented with post hoc multivariate linear regression analyses. Test of interaction comparing sex in the pairwise comparison between DX2 (dexamethasone [24 mg] + dexamethasone [24 mg]) versus placebo (p = .02), showed a larger effect of dexamethasone on morphine consumption in male patients compared to females. Test of interaction comparing age in the pairwise comparison between DX1 (dexamethasone [24 mg] + placebo) versus placebo (p = .04), showed a larger effect of dexamethasone on morphine consumption in younger patients (≤65 years) compared to older. All remaining subgroup analyses showed no evidence of a difference. The supplemental multivariate analyses did not support any significant interaction for sex (p = .256) or age (p = .730) but supported a significant interaction with the type of anaesthesia (p < .001). Our results from the quantile regression analyses indicate that the male sex and younger age (≤65 years) may be associated with a larger analgesic effect of dexamethasone than the effects in other types of patients. However, this is not supported by post‐hoc multivariate linear regression analyses. The two types of analyses both supported a possible interaction with the type of anaesthesia.


  • Open Access

    Prolonged effects of dexamethasone following total knee arthroplasty: A pre‐planned sub‐study of the DEX‐2‐TKA trial

    by Cecilie Bauer Derby, Kasper Smidt Gasbjerg, Daniel Hägi‐Pedersen, Troels Haxholdt Lunn, Niels Anker Pedersen, Peter Lindholm, Stig Brorson, Henrik Morville Schrøder, Kasper Højgaard Thybo, Jens Bagger, et al.

    Objectives: The DEX‐2‐TKA trial demonstrated that one and two doses of 24 mg intravenous dexamethasone reduced opioid consumption and pain after total knee arthroplasty (TKA). We aimed to investigate the prolonged effects of dexamethasone after the 48‐h intervention period.Design: This was a prospective, pre‐planned questionnaire follow‐up on postoperative days 3–7 of patients in the DEX‐2‐TKA trial that randomly received: DX1 (dexamethasone 24 mg + placebo), DX2 (dexamethasone 24 mg + dexamethasone 24 mg), and placebo (placebo + placebo) perioperatively and 24 h later.Setting: A multicenter trial performed at five Danish hospitals.Participants: We analyzed 434 of 485 adult participants enrolled in the DEX‐2‐TKA trial.Outcome Measures: Primary outcome was difference between groups in average of all numerical rating scale (NRS) pain scores reported in the morning, at bedtime, and the daily average pain on postoperative days 3–7. Secondary outcomes were sleep quality and patient satisfaction.Results: The median (interquartile range) pain intensity levels for postoperative days 3–7 were: DX2 3.2 (2.1–4.3); DX1 3.3 (2.3–4.1); and placebo 3.3 (2.5–4.7). Hodges–Lehmann median differences between groups were: 0 (95% confidence interval − 0.54 to 0.2), P = 0.38 between DX1 and placebo; 0.1 (−0.47 to 0.33), p = .87 between DX1 and DX2; and 0.1 (−0.6 to 0.13), p = .20 between DX2 and placebo. We found no relevant differences between groups on sleep quality on postoperative days 3–7 nor for patient satisfaction with the analgesic treatment.Conclusions: We found that neither one nor two doses of 24 mg intravenous dexamethasone demonstrated prolonged effects on overall pain or sleep quality on postoperative days 3–7 after total knee arthroplasty. We also found that dexamethasone had no effect on patient satisfaction.Trial registration number: Clinicaltrials.gov NCT03506789 (main result trial).


  • Open Access

    Minimal important difference in opioid consumption based on adverse event reduction—A study protocol

    by Anders Peder Højer Karlsen, Casper Pedersen, Jens Laigaard, Kasper Højgaard Thybo, Kasper Smidt Gasbjerg, Anja Geisler, Troels Haxholdt Lunn, Daniel Hägi‐Pedersen, Janus Christian Jakobsen, Ole Mathiesen

    Background: The patient-relevant minimal important difference for opioid consumption remains undetermined, despite its frequent use as primary outcome in trials on postoperative pain management. A minimal important difference is necessary to evaluate whether significant trial results are clinically relevant. Further, it can be used as effect size to ensure that trials are powered to find clinically relevant effects. By exploring the dose-response relationship between postoperative opioid consumption and opioid-related adverse effects, we aim to approximate the minimal important difference in opioid consumption anchored to opioid-related adverse effects.Methods: This is a post-hoc analysis of aggregated data from two clinical trials (PANSAID NCT02571361 and DEX2TKA NCT03506789) and one observational cohort study (Pain Map NCT02340052) on pain management after total hip and knee arthroplasty. The primary outcome is the Hodges-Lehmann median difference in opioid consumption between patients with no opioid-related adverse effects and patients experiencing the mildest degree of one or more opioid-related adverse effects (i.e., mild nausea, sedation and/or dizziness or vomiting). Secondary outcomes include the Hodges-Lehmann median difference in opioid consumption that corresponds to one point on a cumulated opioid-related adverse event 0-10 scale. Further, we will explore the proportion of patients that experience opioid-related adverse effects for consecutive opioid dose intervals of 2 mg iv morphine equivalents. Quantile regression will be used to assess any significant interactions with patient baseline characteristics.Conclusions: This study will hopefully bring us one step closer to determining relevant opioid reductions and thereby improve our understanding of intervention effects and planning of future trials.


  • Open Access

    Effect of dexamethasone on intraoperative remifentanil dose in total knee arthroplasty surgery under general anaesthesia

    by Maria Gantzel, Kasper Smidt Gasbjerg, Daniel Hägi‐Pedersen, Christian Sylvest Meyhoff, Markus Harboe Olsen, Ole Mathiesen, Janus Christian Jakobsen, Troels Haxholdt Lunn

    Background: The effects of glucocorticoids may include both genomic and rapid nongenomic effects. The potential rapid analgesic effect during surgery has not previously been investigated. We aimed to explore the effect of dexamethasone on intraoperative infusion rate of remifentanil in patients undergoing total knee arthroplasty (TKA) surgery under general anaesthesia. Methods: In this post hoc subgroup analysis, we included patients randomised in the DEX-2-TKA trial, who were operated under total intravenous anaesthesia with remifentanil and propofol. Trial medication, intravenous dexamethasone 24 mg or placebo, was administered immediately after anaesthesia onset. The primary outcome was the median weight-corrected infusion rate of remifentanil during surgery. Secondary outcomes included median weight-corrected infusion rate of propofol, median intraoperative bispectral index and time spent in the post-anaesthesia care unit. Results: Eighty-seven patients were included in the analysis of the primary outcome. A significantly higher remifentanil infusion rate was observed in the dexamethasone group compared with the placebo group, p = .02. None of the secondary outcomes resulted in statistically significant differences between groups. Conclusion: This explorative post hoc analysis of the randomised DEX-2-TKA trail showed that patients undergoing TKA surgery under general anaesthesia and who received dexamethasone seemed to have a higher remifentanil infusion rate compared with patients who received placebo. The clinical implications of the potentially increased remifentanil infusion rate need to be validated and explored further.


  • Top Cited Papers
    Open Access

    Effect of dexamethasone as an analgesic adjuvant to multimodal pain treatment after total knee arthroplasty: randomised clinical trial

    by Kasper Smidt Gasbjerg, Daniel Hägi-Pedersen, Troels Haxholdt Lunn, Christina Cleveland Laursen, Majken Holmqvist, Louise Ørts Vinstrup, Mette Ammitzboell, Karina Jakobsen, Mette Skov Jensen, Marie Jøhnk Pallesen, et al.

    Objective To investigate the effects of one and two doses of intravenous dexamethasone in patients after total knee arthroplasty. Design Randomised, blinded, placebo controlled trial with follow-up at 90 days. Setting Five Danish hospitals, September 2018 to March 2020. Participants 485 adult participants undergoing total knee arthroplasty. Intervention A computer generated randomised sequence stratified for site was used to allocate participants to one of three groups: DX1 (dexamethasone (24 mg)+placebo); DX2 (dexamethasone (24 mg)+dexamethasone (24 mg)); or placebo (placebo+placebo). The intervention was given preoperatively and after 24 hours. Participants, investigators, and outcome assessors were blinded. All participants received paracetamol, ibuprofen, and local infiltration analgesia. Main outcome measures The primary outcome was total intravenous morphine consumption 0 to 48 hours postoperatively. Multiplicity adjusted threshold for statistical significance was PResults 485 participants were randomised: 161 to DX1, 162 to DX2, and 162 to placebo. Data from 472 participants (97.3%) were included in the primary outcome analysis. The median (interquartile range) morphine consumptions at 0-48 hours were: DX1 37.9 mg (20.7 to 56.7); DX2 35.0 mg (20.6 to 52.0); and placebo 43.0 mg (28.7 to 64.0). Hodges-Lehmann median differences between groups were: −2.7 mg (98.3% confidence interval −9.3 to 3.7), P=0.30 between DX1 and DX2; 7.8 mg (0.7 to 14.7), P=0.008 between DX1 and placebo; and 10.7 mg (4.0 to 17.3), PConclusion Two doses of dexamethasone reduced morphine consumption during 48 hours after total knee arthroplasty and reduced postoperative pain. Trial registration Clinicaltrials.gov NCT03506789.